Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 10 Jun 2021
Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications
7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...
Posted by Michael Wonder on 12 Nov 2019
Labour peer says he opposes Corbyn-style state-funded drugs firm
12 November 2019 - A Labour peer has spoken out against the idea of a nationalised drugs industry, saying that ...
Posted by Michael Wonder on 09 Sep 2019
Subscription model for antibiotic development
6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...
Posted by Michael Wonder on 28 Mar 2019
Take over pharma to create new medicines, says top adviser
27 March 2019 - Part of the drugs industry should be taken over to make new antibiotics, an influential economist ...
Posted by Michael Wonder on 23 Feb 2019
Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model in a pharmaceutical company
21 February 2019 - Evidence requirements and assessment methods access differ between health technology assessment agencies. ...
Posted by Michael Wonder on 29 Jan 2019
NICE Scientific Advice launches collaborative programme with life sciences industry body
29 January 2019 - NICE has announced a collaboration with the body which represents life sciences organisations in the UK. ...
Posted by Michael Wonder on 14 Jun 2018
Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions
13 June 2018 - The pathway for bringing a new medicine to the market is dependent on two sequential processes: achieving ...
Posted by Michael Wonder on 23 Oct 2017
Taxpayer-funded drugs 'too expensive for patients’
22 October 2017 - Taxpayer-funded medical research is producing medicines which are increasingly unaffordable for patients who need them, says ...
Posted by Michael Wonder on 27 Jun 2017
NICE launches a competition for developers of health care technologies
27 June 2017 - NICE Scientific Advice has launched a competition for small or medium sized companies, charities and academic research ...
Posted by Michael Wonder on 30 May 2017
NICE to launch new evidence tool for medtech product developers
30 May 2017 - NICE is launching an online tool to help medtech companies get their products to patients faster. ...